Roivant Sciences Ltd. research snapshot
ROIV AI stock analysis currently reads Roivant as a well-capitalized biopharma platform whose value is tied to clinical, regulatory, and launch outcomes rather than current revenue. At the August 2, 2026 cutoff, the latest public quote was $33.91 at the July 31 close, the verified market capitalization was about $24.39 billion, and consolidated cash and marketable securities were $4.29 billion at March 31, 2026. The brepocitinib dermatomyositis launch expected by the end of September 2026, several H2 2026 readouts, and the $2.25 billion Moderna settlement support the upside case, while recurring operating losses, thin revenue, pipeline concentration, and binary event risk argue for caution. This ROIV AI stock analysis uses scenarios instead of a certain price prediction and is for informational use, not investment advice.
Current price
$33.91
Market cap
$24.39 billion
AI score
58 / 100
Rating
Well-capitalized, catalyst-rich biopharma with high event risk
Trend status
Above the 50-day and 200-day moving averages; momentum cooled from July highs
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Roivant develops and commercializes medicines through focused subsidiaries, or Vants, and the commercial engine is still early. Customers ultimately pay through healthcare systems when approved therapies demonstrate clinical and commercial value. | Medium |
| Moat | The moat is narrower than a mature drug franchise: it rests on intellectual property, clinical evidence, regulatory exclusivity, specialist relationships, capital, and the ability to select and develop assets. It must be renewed program by program. | Medium-low |
| Management | Management has reshaped the portfolio with asset sales, the Priovant brepocitinib acquisition, the batoclimab discontinuation, and the Moderna settlement. The next test is disciplined spending and commercial execution as brepocitinib approaches launch. | Medium |
| Financial trend | FY2026 revenue was $8.26 million and loss from continuing operations was $397.91 million, with a $299.77 million net loss attributable to Roivant. Cash and marketable securities were $4.29 billion, while operating cash flow was negative $750.35 million, so runway is strong but self-funded profitability is not yet visible. | High |
| Valuation | At $33.91, financial_rigor.py calculates a negative trailing PE and FCF yield because EPS and free cash flow are negative. A standard earnings multiple is not decision-useful; valuation depends on pipeline probabilities, cash use, and eventual commercial economics. | Medium |
| Technical trend | The August snapshot put ROIV above its 50-day average of $32.57 and 200-day average of $26.42, with RSI at 49.64 after a pullback from the July high near $36. | Medium |
| Risk level | Risk is high. Trial results, FDA decisions, safety, launch adoption, reimbursement, competition, litigation-payment timing, cash burn, and valuation compression can all alter the thesis quickly. | High |
| AI confidence | The reported-data description is well supported, but AI cannot reliably assign clinical probabilities or predict the market response to a regulatory or data event. | High data confidence |
| Investment certainty | Investment certainty is low to medium because cash and disclosed catalysts are tangible, while the revenue path and end-market value of the pipeline remain unproven. | Low-medium |
ROIV AI stock forecast
The ROIV AI stock forecast is scenario-based, not a point target. Because FY2026 EPS and free cash flow were negative, the mandatory three-scenario EPS calculation produces non-economic negative price outputs and is not used as a valuation target. The ranges below are catalyst and risk scenarios around the July 31, 2026 quote of $33.91, and they sit near the published analyst target range of $31.50 to $42.
$40 to $48
More likely if brepocitinib launches in dermatomyositis as planned and adoption is strong, H2 2026 readouts in non-infectious uveitis, cutaneous lupus erythematosus, and PH-ILD are constructive, IMVT-1402 keeps progressing, and the Moderna Section 1498 appeal resolves favorably so the $1.3 billion contingent payment can be recognized.
$30 to $40
More likely if development timelines broadly hold but launch economics and late-stage data remain uncertain. This case assumes the company retains financial flexibility while the market continues to discount future program value.
$22 to $30
More likely if a major trial, safety signal, FDA decision, reimbursement outcome, or launch disappoints, if cash burn rises, or if the market assigns less value to the pipeline and non-recurring settlement economics.
ROIV AI technical analysis
ROIV AI technical analysis uses the latest public snapshot available at the August 2, 2026 cutoff: $33.91 at the July 31 close, 50-day moving average of $32.57, 200-day moving average of $26.42, RSI of 49.64, beta of 1.11, and 20-day average volume of 4.65 million shares. This static page does not fetch request-time data. Confirm every price level, volume measure, and moving average in a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $33.91 | Public closing quote on July 31, 2026. The quote should be refreshed before any decision. |
| Near support | $32.57 | Reported 50-day moving average at the cutoff. A sustained loss of this area would weaken the recent trend. |
| Deeper support | $26.42 | Reported 200-day moving average at the cutoff. Recheck the live value because moving averages change daily. |
| Near resistance | $36 to $40 | The July high near $36 through the published analyst-consensus range is a reference zone, not a chart-derived guarantee. Volume and news context matter. |
| 50-day moving average | $32.57 | Price was above this average in the August snapshot, which supports the intermediate trend. |
| 200-day moving average | $26.42 | Price was above this average in the August snapshot, supporting the longer trend while the level remains live-chart dependent. |
| Momentum | RSI 49.64 | Momentum is neutral after a pullback from the extended July reading. Watch for direction confirmation rather than extrapolating the July move. |
| Volume | 20-day average 4.65 million shares | Use above-average volume to validate a breakout, especially around clinical, FDA, or earnings news. |
| Volatility | 5-year beta 1.11 | Biopharma event risk can exceed beta estimates, so predefined risk limits matter more than a historical beta alone. |
| Invalidation | Decisive close below the live 50-day average | For a trend-following framework, a confirmed break below the live 50-day average near $32.57 is an invalidation condition, not a personal sell instruction. |
ROIV AI trading strategy
The ROIV AI trading strategy is a rules-based research framework, not personalized advice. It combines live price confirmation with FDA and trial calendars, launch metrics, cash burn, repurchase activity, share count, settlement receipts, and the August 6, 2026 earnings report.
Wait for ROIV to hold above the live 50-day average and for any move through the current $36 to $40 reference zone to be confirmed by above-average volume and an unchanged catalyst thesis. Check the August 6, 2026 earnings call and upcoming FDA, trial, and launch dates before relying on a chart pattern.
Define risk before entry. A failed breakout or decisive close below the live 50-day average near $32.57 can invalidate this setup.
If ROIV pulls back toward the 50-day average without a negative program development, wait for stabilization and compare the move with volume, the cash runway, trial timelines, and any FDA, launch, or reimbursement news.
Do not average down because a share price fell. The setup fails if support breaks alongside adverse clinical, regulatory, or commercial evidence.
Track the brepocitinib dermatomyositis launch and NDA action date, H2 2026 readouts in non-infectious uveitis, cutaneous lupus erythematosus, and PH-ILD, IMVT-1402 difficult-to-treat rheumatoid arthritis updates, cash and marketable securities, operating cash flow, the Moderna settlement payment status, R&D expense, share repurchases, diluted shares, and competitive treatment data.
Refresh all scenarios after material data, an FDA decision, earnings, a program discontinuation, a settlement update, or a large price gap. Avoid stale technical levels around binary events.
Investment research summary
Roivant develops and commercializes medicines through focused subsidiaries, or Vants. Its economic value depends on selecting assets, generating clinical evidence, navigating regulation, and converting approved therapies into durable sales.
The relevant protections are patents, know-how, clinical data, regulatory exclusivity, specialty-commercial capabilities, and capital. These advantages are meaningful only if individual programs demonstrate a better risk and benefit profile than competing therapies.
The thesis fails if late-stage trials disappoint, safety or manufacturing issues emerge, regulators delay or reject applications, launch uptake is slow, payers restrict access, competitors improve, cash burn accelerates, the Moderna contingent payment does not resolve favorably, or the market stops valuing future pipeline optionality.
The management test is capital allocation under uncertainty: select programs economically, preserve runway, make disciplined partnerships and dispositions, stop programs that fail as with batoclimab, and execute commercial launches without letting research and overhead costs outrun evidence of value.
Autoimmune and rare-disease drug development can create substantial value when an approved therapy solves an unmet need, but the path is shaped by trial design, regulatory standards, payer access, competitive readouts, and treatment adoption rather than a smooth market-growth curve.
The verified $24.39 billion market capitalization includes a large cash position and expectations for future pipeline value. With $8.26 million of FY2026 revenue and negative free cash flow, a margin of safety cannot be inferred from conventional PE or FCF multiples; it depends on conservative assumptions about clinical success, commercialization, and future spending.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ROIV price | $33.91 at the July 31, 2026 close | StockAnalysis quote snapshot | August 2, 2026 |
| Market capitalization and shares | $24.39 billion and 719.27 million shares. financial_rigor.py verified $33.91 x 719.27 million shares with a 0.00% difference from reported market cap. Roivant's DEF 14A reported 722,668,062 shares outstanding as of June 30, 2026. | StockAnalysis, verified with financial_rigor.py, cross-checked with SEC DEF 14A | August 2, 2026 |
| FY2026 revenue | $8.26 million, down from $29.05 million in FY2025 | Roivant FY2026 Form 10-K, cross-checked with StockAnalysis | August 2, 2026 |
| FY2026 loss and per-share results | Loss from continuing operations of $397.91 million and net loss attributable to Roivant of $299.77 million, or $0.43 basic per share | Roivant FY2026 Form 10-K, cross-checked with StockAnalysis | August 2, 2026 |
| Cash and marketable securities | $4.292 billion at March 31, 2026, comprising $1.419 billion cash and cash equivalents plus $2.873 billion marketable securities, with a $770.2 million litigation settlement receivable | Roivant FY2026 Form 10-K, cross-validated with financial_rigor.py | August 2, 2026 |
| FY2026 operating cash flow and free cash flow | Negative $750.35 million operating cash flow and negative $758.56 million free cash flow | Roivant FY2026 Form 10-K, cross-checked with StockAnalysis | August 2, 2026 |
| Pipeline and settlement milestones | Brepocitinib NDA accepted with Priority Review and a target action date in Q3 2026, with DM launch expected by the end of September 2026; IMVT-1402 D2T RA Week 16 ACR20, ACR50, and ACR70 of 72.7%, 54.5%, and 35.8%; NIU, CLE, and PH-ILD readouts expected in H2 2026; a $2.25 billion Moderna settlement with a $950 million non-contingent payment due on or before July 8, 2026 and a $1.3 billion contingent payment not recognized. | Roivant Q4 FY2026 earnings release and Form 10-K | August 2, 2026 |
| Analyst price target | $38.59 average, with a low of $31.50 and a high of $42; consensus "Strong Buy" from 12 analysts | StockAnalysis forecast page (S&P Global) | July 31, 2026 |
This page is an informational research tool, not investment advice, a recommendation, or an offer to buy or sell securities. Forecast ranges are scenarios based on public data available through August 2, 2026 and can be wrong. Verify current filings, prices, clinical updates, and your own risk constraints before making any investment decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
